Konrad Hoetzenecker, MD, PhD
Central Message.
Extended techniques of living-donor lobar lung transplantation (LDLLT) can improve donor-to-recipient size-matching; however, their need is closely linked to the need of LDLLT programs in principle.
See Article page 388.
Scarcity of donor organs remains one of the main hurdles in contemporary lung transplantation. Western countries have addressed this problem by extending their cadaveric donor pool (eg, liberalization of donor criteria, promoting donation after circulatory death). Japanese transplant centers have for a long time fostered living-donor lobar lung transplantation (LDLLT). Excellent long-term results have been reported1; however, the feasibility of LDLLT is mainly limited by restrictions in size-matching, and often only children or adults with an unusual small chest can be considered.
In this issue of the JTCVS Techniques, Nakajima and colleagues2 summarize their institutional experience with extended techniques of LDLLT, namely native upper-lobe sparing LDLLT, right-to-left inverted LDLLT, and single-lobe LDLLT.2 All 3 techniques are based on a common consideration: to overcome size discrepancies between available donor lobe(s) and the recipient chest.
The Kyoto team has to be congratulated for once more taking the lead and improving the surgical technique of LDLLT. Both native upper-lobe sparing LDLLT and right-to-left inverted LDLLT require detailed anatomical knowledge and exceptional surgical skills. Adding complexity to an already complex procedure always bears a risk of increased complication rates. The authors red-flagged the risk of kinking the pulmonary artery anastomosis in their manuscript. In addition, due to the smaller diameters, impaired healing is more relevant in lobar-to-lobar bronchial anastomosis than in lobar-to-main bronchus anastomosis. Finally, leaving a bronchial stump in immunosuppressed patients is risky even when buttressed with pericardium. It is impressive that despite the added complexity, extended LDLLT techniques had a low complication rate and a similar early post-transplant outcome as compared with standard LDLLT patients.
One main question arises: Are such extended techniques really necessary, or are there easier alternatives of providing patients with donor organs? Even today, a considerable number of lungs are still rejected due to presumably poor quality. We have previously shown that donor organs that had been rejected by up to 12 other centers within the Eurotransplant region could be transplanted with excellent long-term outcomes.3 A similar finding was published by Mulvihill and colleagues,4 analyzing United Network of Organ Sharing data. In addition, ex vivo lung perfusion is increasingly used as a platform to recondition primarily unacceptable organs: Edematous donor lungs can be perfused by high-oncotic solutions,5 organs with signs of pneumonia can be treated by high-dose antibiotis,6 and hepatitis C virus–positive grafts can be sterilized.7
Despite the aforementioned advances, organ availability remains suboptimal, especially for children and small adults with a retracted chest and blood group 0. These patients should be routinely screened for a LDLLT as an alternative to cadaveric lobar lung transplantation. In addition, LDLLT and consequently extended LDLLT techniques are often the only option for transplant candidates from countries lacking an established organ donation system.
In summary, extended LDLLT is not just a technical finger exercise but could earn its place in LDLLT. However, its fate is closely related to the need of a LDLLT program in principle.
Footnotes
Disclosures: The author reported no conflicts of interest.
The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
References
- 1.Nakajima D., Chen-Yoshikawa T.F., Ohsumi A., Date H. Living-donor lobar lung transplants provide comparable pulmonary function to cadaveric lung transplants. J Thorac Cardiovasc Surg. August 28, 2019 doi: 10.1016/j.jtcvs.2019.07.099. [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
- 2.Nakajima D., Tanaka S., Ohsumi A., Date H. Outcomes of novel surgical procedures for graft size mismatch in living-donor lobar lung transplantation. J Thorac Cardiovasc Surg Tech. 2020;3:388–391. doi: 10.1016/j.xjtc.2020.06.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Schwarz S, Muckenhuber M, Benazzo A, Glueck O, Evermann M, Beer L, et al. Lung transplantation using donor lungs multiply declined for quality reasons. Presented at: 12th International Congress on Lung Transplantation; 2016; Paris.
- 4.Mulvihill M.S., Lee H.J., Weber J., Choi A.Y., Cox M.L., Yerokun B.A., et al. Variability in donor organ offer acceptance and lung transplantation survival. J Heart Lung Transplant. 2020;39:353–362. doi: 10.1016/j.healun.2019.12.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Nilsson T., Hansson C., Wallinder A., Malm C.J., Silverborn M., Ricksten S.E., et al. Hemofiltration in ex vivo lung perfusion—a study in experimentally induced pulmonary edema. J Thorac Cardiovasc Surg. 2016;151:570–575.e1. doi: 10.1016/j.jtcvs.2015.06.046. [DOI] [PubMed] [Google Scholar]
- 6.Nakajima D., Cypel M., Bonato R., Machuca T.N., Iskender I., Hashimoto K., et al. Ex vivo perfusion treatment of infection in human donor lungs. Am J Transplant. 2016;16:1229–1237. doi: 10.1111/ajt.13562. [DOI] [PubMed] [Google Scholar]
- 7.Galasso M., Feld J.J., Watanabe Y., Pipkin M., Summers C., Ali A., et al. Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion. Nat Commun. 2019;10:481. doi: 10.1038/s41467-018-08261-z. [DOI] [PMC free article] [PubMed] [Google Scholar]